The Effects of Perioperative Dexmedetomidine Administration on Immune Suppression and Outcomes in Patients With Uterine Cancer Undergoing Radical Resection
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- natural killer cell cytotoxicity
研究概览
简要总结
Surgical stress and anesthesia may cause immunosuppression in immunocompromised cancer patients. The natural killer (NK) cell is a critical part of anti-tumor immunity. Dexmedetomidine has sympatholytic effect and preserves NK cell function. This study investigate the effect of dexmedetomidine on immune suppression and postoperative outcomes in patients undergoing uterine cancer resection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Triple (Participant, Care Provider, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 70 Years(Adult, Older Adult)
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •patient between 20 and 70 of age with ASA physical status Ⅰ-Ⅲ
- •patient scheduled for uterine cancer surgery
排除标准
- •ASA physical status Ⅳ
- •severe hepatorenal disease
- •infection
- •metastasis to other organ
- •problem with communication
研究组 & 干预措施
Dexmedetomidine Group
dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery
干预措施: Dexmedetomidine group (Drug)
Control Group
0.9% saline infusion
干预措施: Control group (Drug)
结局指标
主要结局
natural killer cell cytotoxicity
时间窗: postoperative day 5
Natural killer cell cytotoxicity is measured with NK Vue Kit™(ATGen, Gyeonggi-do, Korea).
次要结局
- inflammatory response(postoperative day 5)
